Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression

Cell Death and Disease

Volumn 4, Issue 3, 2013, Pages

  Sachweh, M C C ^a   Drummond, C J ^a   Higgins, M ^b   Campbell, J ^b   Lain, S ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cancer therapy; IPS cell generation; Nutlin 3; P21; P53; Trichostatin A

Indexed keywords

MESSENGER RNA; NUTLIN 3; PROTEIN P21; PROTEIN P53; TRICHOSTATIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN MDM2;

ARTICLE; CELL CYCLE PROGRESSION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENDOREDUPLICATION; HUMAN; HUMAN CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL CYCLE CHECKPOINT; CELL STRAIN HCT116; CELL STRAIN MCF 7; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM;

MURINAE;

CELL CYCLE CHECKPOINTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMIDAZOLES; MCF-7 CELLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

MLCS; MLOWN;

EID: 84875874820     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.61     Document Type: Article

References (46)

1. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90.
2. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
3. Cheok CF, Dey A, Lane DP. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: A potent drug combination. Mol Cancer Res 2007; 5: 1133-1145.
4. van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2011; 10: 1590-1598.
5. Peltonen K, Kiviharju TM, Jarvinen PM, Ra R, Laiho M. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment Cell Res 2005; 18: 196-202.
6. Gialitakis M, Kretsovali A, Spilianakis C, Kravariti L, Mages J, Hoffmann R et al. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by trichostatin A. Nucleic Acids Res 2006; 34: 765-772.
7. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002; 1: 937-941.
8. Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000; 88: 992-997.
9. Wu P, Meng L, Wang H, Zhou J, Xu G, Wang S et al. Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor. Biochem Biophys Res Commun 2005; 335: 36-44.
10. Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H et al. Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann NY Acad Sci 1999; 886: 195-199.
11. Xiao H, Hasegawa T, Isobe K. P300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 2000; 275: 1371-1376.
12. Xiao H, Hasegawa T, Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem 1999; 73: 291-302.
13. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
14. Xia M, Knezevic D, Vassilev LT. P21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation. Oncogene 2011; 30: 346-355.
15. Kemp MG, Ghosh M, Liu G, Leffak M. The histone deacetylase inhibitor trichostatin A alters the pattern of DNA replication origin activity in human cells. Nucleic Acids Res 2005; 33: 325-336.
16. Bickmore WA, Carothers AD. Factors affecting the timing and imprinting of replication on a mammalian chromosome. J Cell Sci 1995; 108(Part 8): 2801-2809.
17. Noh EJ, Lim DS, Jeong G, Lee JS. An HDAC inhibitor, trichostatin A, induces a delay at G2/ M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun 2009; 378: 326-331.
18. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 2001; 98: 87-92.
19. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005; 65: 1918-1924.
20. Kranz D, Dobbelstein M. Nongenotoxic p53 activation protects cells against S-phasespecific chemotherapy. Cancer Res 2006; 66: 10274-10280.
21. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr., Kinzler KW et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 2009; 106: 3964-3969.
22. Cheok CF, Kua N, Kaldis P, Lane DP. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ 2010; 17: 1486-1500.
23. van Leeuwen IM, Rao B, Sachweh MC, Lain S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anti-cancer drugs in normal cells. Cell Cycle 2012; 11: 1851-1861.
24. Matheu A, Klatt P, Serrano M. Regulation of the INK4a/ARF locus by histone deacetylase inhibitors. J Biol Chem 2005; 280: 42433-42441.
25. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001-5014.
26. Chen J, Li Q. Life and death of transcriptional co-activator p300. Epigenetics 2011; 6: 957-961.
27. Li H, Wu X. Histone deacetylase inhibitor, trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun 2004; 324: 860-867.
28. Weber A, Liu J, Collins I, Levens D. TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression. Mol Cell Biol 2005; 25: 147-161.
29. Mitchell KO, El-Deiry WS. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ 1999; 10: 223-230.
30. Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc Natl Acad Sci USA 2000; 97: 9498-9503.
31. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 2000; 97: 3260-3265.
32. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 2001; 98: 4510-4515.
33. Ragimov N, Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 1993; 8: 1183-1193.
34. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence JJ et al. P53-mediated cell death: Relationship to cell cycle control. Mol Cell Biol 1993; 13: 1415-1423.
35. Gudkov AV, Komarova EA. Dangerous habits of a security guard: The two faces of p53 as a drug target. Hum Mol Genet 2007; 16: R67-R72.
36. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26: 795-797.
37. Ruau D, Ensenat-Waser R, Dinger TC, Vallabhapurapu DS, Rolletschek A, Hacker C et al. Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere cells. Stem Cells 2008; 26: 920-926.
38. Okita K, Yamanaka S. Induced pluripotent stem cells: Opportunities and challenges. Philos Trans R Soc Lond Ser B 2011; 366: 2198-2207.
39. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460: 1140-1144.
40. Blaydes JP, Hupp TR. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene 1998; 17: 1045-1052.
41. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
42. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13: 4107-4114.
43. Fredersdorf S, Milne AW, Hall PA, Lu X. Characterization of a panel of novel anti-p21Waf1/ Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol 1996; 148: 825-835.
44. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-244.
45. Berkson RG, Hollick JJ, Westwood NJ, Woods JA, Lane DP, Lain S. Pilot screening programme for small molecule activators of p53. Int J Cancer 2005; 115: 701-710.
46. Frebourg T, Barbier N, Kassel J, Ng YS, Romero P, Friend SH. A functional screen for germ line p53 mutations based on transcriptional activation. Cancer Res 1992; 52: 6976-6978.